This article is a correction to:
Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma
Haiyang Zhao1,2,3,4†
Kexin Luo1,2,3,4†Meihan Liu1,2,4,5†
Yuanze Cai2Siman Liu2Shijuan Li6
Yongsheng Zhao1,2,3*
Hongpan Zhang1,2,5,7*- 1Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
- 2North Sichuan Medical College, Nanchong, China
- 3Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
- 4North Sichuan Medical College, Innovation Centre for Science and Technology, Nanchong, China
- 5Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
- 6Nanchong Central Hospital, Nanchong, Sichuan, China
- 7Therapeutic Proteins Key Laboratory of Sichuan Province, Nanchong, China
A Corrigendum on
Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma
by Zhao H, Luo K, Liu M, Cai Y, Liu S, Li S, Zhao Y and Zhang H (2024). Front. Genet. 15:1458047. doi: 10.3389/fgene.2024.1458047
In the published article, there was an error regarding the Affiliations listed for Haiyang Zhao, Kexin Luo, Meihan Liu, Yongsheng Zhao and Hongpan Zhang. In addition to their existing Affiliations, they should also have Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China listed to their names.
The corrected Affiliations are listed below:
Haiyang Zhao1,2,3,4,†, Kexin Luo1,2,3,4,†, Meihan Liu1,2,4,5,†, Yuanze Cai2, Siman Liu2, Shijuan Li6, Yongsheng Zhao1,2,3,*, Hongpan Zhang1,2,5,7,*
1.Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
2.North Sichuan Medical College, Nanchong, China
3.Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
4.North Sichuan Medical College, Innovation Centre for Science and Technology, Nanchong, China
5.Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
6.Nanchong Central Hospital, Nanchong, Sichuan, China
7.Therapeutic Proteins Key Laboratory of Sichuan Province, Nanchong, China
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: lung adenocarcinoma, PSMB6, immunotherapy, immune infiltration, tumor immune microenvironment
Citation: Zhao H, Luo K, Liu M, Cai Y, Liu S, Li S, Zhao Y and Zhang H (2024) Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma. Front. Genet. 15:1531321. doi: 10.3389/fgene.2024.1531321
Received: 20 November 2024; Accepted: 21 November 2024;
Published: 04 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Zhao, Luo, Liu, Cai, Liu, Li, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongsheng Zhao, c2NuY3p5c0AxMjYuY29t; Hongpan Zhang, aG9uZ3BhbnpoYW5nc2NjbkAxNjMuY29t
†These authors have contributed equally to this work